Refolding of the recombinant protein Sm29, a step toward the production of the vaccine candidate against schistosomiasis

Journal of Biotechnology

Volumn 168, Issue 4, 2013, Pages 511-519

  Chura Chambi, Rosa M ^a   Nakajima, Erika ^b   de Carvalho, Roberta R ^b   Miyasato, Patricia A ^b   Oliveira, Sergio C ^c,d   Morganti, Ligia ^a   Martins, Elizabeth A L ^b  

^a INSTITUTO DE PESQUISAS ENERGÉTICAS E NUCLEARES   (Brazil)

^b INSTITUTO BUTANTAN   (Brazil)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^d MCT   (Brazil)

Author keywords

Hydrostatic pressure; Protein refolding; Schistosomiasis; Vaccine

Indexed keywords

AGGREGATED PROTEIN; HIGH HYDROSTATIC PRESSURE; INDUSTRIAL PRODUCTION; PROTECTIVE EFFECTS; PROTEIN REFOLDING; REFOLDING PROCESS; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS;

ANTIGENS; CHEMOTHERAPY; ESCHERICHIA COLI; HYDROSTATIC PRESSURE; PATHOGENS; VACCINES;

RECOMBINANT PROTEINS;

ANTISCHISTOSOMAL AGENT; RECOMBINANT PROTEIN SM29; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; CONFORMATION; CONTROLLED STUDY; FEMALE; HUMORAL IMMUNITY; HYDROSTATIC PRESSURE; LARGE SCALE PRODUCTION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN REFOLDING; PROTEIN STRUCTURE; PROVOCATION TEST; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS; VACCINE PRODUCTION;

ANIMALIA; ESCHERICHIA COLI; MUS; SCHISTOSOMA MANSONI;

CD; CIRCULAR DICHROISM; GDNHCL; GSSG AND GSH; GUANIDINE HYDROCHLORIDE; HHP; HIGH HYDROSTATIC PRESSURE; HYDROSTATIC PRESSURE; IB; IMAC; IMMOBILIZED METAL AFFINITY CHROMATOGRAPHY; INCLUSION BODIES; LIGHT SCATTERING; LS; OXIDIZED AND REDUCED FORM OF GLUTATHIONE* RESPECTIVELY; PROTEIN REFOLDING; SCHISTOSOMIASIS; VACCINE;

ANIMALS; ANTIGENS, HELMINTH; CIRCULAR DICHROISM; ESCHERICHIA COLI; HELMINTH PROTEINS; HUMANS; INCLUSION BODIES; MEMBRANE GLYCOPROTEINS; MICE; PROTEIN FOLDING; RECOMBINANT PROTEINS; SCHISTOSOMA; SCHISTOSOMIASIS; VACCINES;

EID: 84888849784     PISSN: 01681656     EISSN: 18734863     Source Type: Journal    
DOI: 10.1016/j.jbiotec.2013.09.017     Document Type: Article

References (43)

1. Ahmad G., Zhang W., Torben W., Ahrorov A., Damian R.T., Wolf R.F., White G.L., Carey D.W., Mwinzi P.N., Ganley-Leal L., Kennedy R.C., Siddiqui A.A. Preclinical prophylactic efficacy testing of Sm-p80-based vaccine in a nonhuman primate model of Schistosoma mansoni infection and immunoglobulin G and E responses to Sm-p80 in human serum samples from an area where schistosomiasis is endemic. J. Infect. Dis. 2011, 204:1437-1449.
2. Amaral R.S., Tauil P.L., Lima D.D., Engels D. An analysis of the impact of the Schistosomiasis Control Programme in Brazil. Mem. Inst. Oswaldo Cruz 2006, 101(Suppl 1):79-85.
3. Bergquist N.R. Schistosomiasis: from risk assessment to control. Trends Parasitol. 2002, 18:309-314.
4. Bergquist R., Utzinger J., McManus D.P. Trick or treat: the role of vaccines in integrated schistosomiasis control. PLoS Negl. Trop. Dis. 2008, 2:e244.
5. Bickle Q.D. Radiation-attenuated schistosome vaccination-a brief historical perspective. Parasitology 2009, 136:1621-1632.
6. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72:248-254.
7. Capron A., Riveau G.J., Bartley P.B., McManus D.P. Prospects for a schistosome vaccine. Curr. Drug Targets Immune Endocr. Metabol. Disord. 2002, 2:281-290.
8. Cardoso F.C., Macedo G.C., Gava E., Kitten G.T., Mati V.L., de Melo A.L., Caliari M.V., Almeida G.T., Venancio T.M., Verjovski-Almeida S., Oliveira S.C. Schistosoma mansoni tegument protein Sm29 is able to induce a Th1-type of immune response and protection against parasite infection. PLoS Negl. Trop. Dis. 2008, 2:e308.
9. Cardoso F.C., Pacífico R.N., Mortara R.A., Oliveira S.C. Human antibody responses of patients living in endemic areas for schistosomiasis to the tegumental protein Sm29 identified through genomic studies. Clin. Exp. Immunol. 2006, 144:382-391.
10. Cardoso F.C., Pinho J.M., Azevedo V., Oliveira S.C. Identification of a new Schistosoma mansoni membrane-bound protein through bioinformatic analysis. Genet. Mol. Res. 2006, 5:609-618.
11. Chura-Chambi R.M., Genova L.A., Affonso R., Morganti L. Refolding of endostatin from inclusion bodies using high hydrostatic pressure. Anal. Biochem. 2008, 379:32-39.
12. Chura-Chambi R.M., Cordeiro Y., Malavasi Y., Lemke N.V., Rodrigues L.S., Morganti D.L. An analysis of the factors that affect the dissociation of inclusion bodies and the refolding of endostatin under high pressure. Process Biochem. 2013, 48(2):250-259.
13. Clark E.D.B. Refolding of recombinant proteins. Curr. Opin. Biotechnol. 1998, 9:157-163.
14. Ferrao-Gonzales A.D., Robbs B.K., Moreau V.H., Ferreira A., Juliano L., Valente A.P., Almeida F.C., Silva J.L., Foguel D. Controlling {beta}-amyloid oligomerization by the use of naphthalene sulfonates: trapping low molecular weight oligomeric species. J. Biol. Chem. 2005, 280:34747-34754.
15. Fitzpatrick J.M., Peak E., Perally S., Chalmers I.W., Barrett J., Yoshino T.P., Ivens A.C., Hoffmann K.F. Anti-schistosomal intervention targets identified by lifecycle transcriptomic analyses. PLoS Negl. Trop. Dis. 2009, 3:e543.
16. Foguel D., Robinson C.R., de Sousa P.C., Silva J.L., Robinson A.S. Hydrostatic pressure rescues native protein from aggregates. Biotechnol. Bioeng. 1999, 63:552-558.
17. Fraga T.R., Chura-Chambi R.M., Goncales A.P., Morais Z.M., Vasconcellos S.A., Morganti L., Martins E.A. Refolding of the recombinant protein OmpA70 from Leptospira interrogans from inclusion bodies using high hydrostatic pressure and partial characterization of its immunological properties. J. Biotechnol. 2010, 148:156-162.
18. Gobert G.N., Stenzel D.J., Jones M.K., Allen D.E., McManus D.P. Schistosoma japonicum: immunolocalization of paramyosin during development. Parasitology 1997, 114(Pt 1):45-52.
19. Gray D.J., McManus D.P., Li Y., Williams G.M., Bergquist R., Ross A.G. Schistosomiasis elimination: lessons from the past guide the future. Lancet Infect. Dis. 2010, 10:733-736.
20. Gryseels B., Polman K., Clerinx J., Kestens L. Human schistosomiasis. Lancet 2006, 368:1106-1118.
21. Hotez P. Enlarging the "Audacious Goal": elimination of the world's high prevalence neglected tropical diseases. Vaccine 2011, 29(Suppl 4):D104-D110.
22. Hotez P.J., Bethony J.M., Diemert D.J., Pearson M., Loukas A. Developing vaccines to combat hookworm infection and intestinal schistosomiasis. Nat. Rev. Microbiol. 2010, 8:814-826.
23. Jiz M., Wu H.W., Meng R., Pond-Tor S., Reynolds M., Friedman J.F., Olveda R., Acosta L., Kurtis J.D. Pilot-scale production and characterization of paramyosin, a vaccine candidate for Schistosomiasis japonica. Infect. Immun. 2008, 76:3164-3169.
24. Kim Y.S., Randolph T.W., Seefeldt M.B., Carpenter H.F. High-pressure studies on protein aggregates and amyloid fibrils. Meth. Enzymol. 2006, 413:237-253.
25. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
26. Loukas A., Tran M., Pearson M.S. Schistosome membrane proteins as vaccines. Int. J. Parasitol. 2007, 37:257-263.
27. Malavasi N.V., Foguel D., Bonafe C.F.S., Braga C.A.C.A., Chura-Chambi R.M., Vieira J.M., Morganti L. Protein refolding at high pressure: optimization using eGFP as a model. Process Biochem. 2011, 46:512-518.
28. McManus D.P., Gray D.J., Li Y., Feng Z., Williams G.M., Stewart D., Rey-Ladino J., Ross A.G. Schistosomiasis in the People's Republic of China: the era of the Three Gorges Dam. Clin. Microbiol. Rev. 2010, 23:442-466.
29. Oliveira S.C., Fonseca C.T., Cardoso F.C., Farias L.P., Leite L.C. Recent advances in vaccine research against schistosomiasis in Brazil. Acta Trop. 2008, 108:256-262.
30. Qoronfleh M.W., Hesterberg L.K., Seefeldt M.B. Confronting high-throughput protein refolding using high pressure and solution screens. Protein Expression Purif. 2007, 55:209-224.
31. Ramos C.R., Abreu P.A., Nascimento A.L., Ho P.L. A high-copy T7 Escherichia coli expression vector for the production of recombinant proteins with a minimal N-terminal His-tagged fusion peptide. Braz. J. Med. Biol. Res. 2004, 37:1103-1109.
32. Ramos C.R., Spisni A., Oyama S., Sforca M.L., Ramos H.R., Vilar M.M., Alves A.C., Figueredo R.C., Tendler M., Zanchin N.I., Pertinhez T.A., Ho P.L. Stability improvement of the fatty acid binding protein Sm14 from S. mansoni by Cys replacement: structural and functional characterization of a vaccine candidate. Biochim. Biophys. Acta 2009, 1794:655-662.
33. Riveau G., Deplanque D., Remoué F., Schacht A.M., Vodougnon H., Capron M., Thiry M., Martial J., Libersa C., Capron A. Safety and immunogenicity of rSh28GST antigen in humans: phase 1 randomized clinical study of a vaccine candidate against urinary schistosomiasis. PLoS Negl. Trop. Dis. 2012, 6:e1704.
34. Ross A.G., Bartley P.B., Sleigh A.C., Olds G.R., Li Y., Williams G.M., McManus D.P. Schistosomiasis. N. Engl. J. Med. 2002, 346:1212-1220.
35. Seto E.Y., Remais J.V., Carlton E.J., Wang S., Liang S., Brindley P.J., Qiu D., Spear R.C., Wang L.D., Wang T.P., Chen H.G., Dong X.Q., Wang L.Y., Hao Y., Bergquist R., Zhou X.N. Toward sustainable and comprehensive control of schistosomiasis in China: lessons from Sichuan. PLoS Negl. Trop. Dis. 2011, 5:e1372.
36. Spear R.C., Seto E.Y., Carlton E.J., Liang S., Remais J.V., Zhong B., Qiu D. The challenge of effective surveillance in moving from low transmission to elimination of schistosomiasis in China. Int. J. Parasitol. 2011, 41:1243-1247.
37. St John R.J., Carpenter J.F., Balny C., Randolph T.W. High pressure refolding of recombinant human growth hormone from insoluble aggregates, structural transformations, kinetic barriers, and energetics. J. Biol. Chem. 2001, 276:46856-46863.
38. St John R.J., Carpenter J.F., Randolph T.W. High pressure fosters protein refolding from aggregates at high concentrations. Proc. Nat. Acad. Sci. U.S.A. 1999, 96:13029-13033.
39. Tendler M., Simpson A.J. The biotechnology-value chain: development of Sm14 as a schistosomiasis vaccine. Acta Trop. 2008, 108:263-266.
40. Tran M.H., Pearson M.S., Bethony J.M., Smyth D.J., Jones M.K., Duke M., Don T.A., McManus D.P., Correa-Oliveira R., Loukas A. Tetraspanins on the surface of Schistosoma mansoni are protective antigens against schistosomiasis. Nat. Med. 2006, 12:835-840.
41. Uneke C.J. Soil transmitted helminth infections and schistosomiasis in school age children in sub-Saharan Africa: efficacy of chemotherapeutic intervention since World Health Assembly Resolution 2001. Tanzan. J. Health Res. 2010, 12:86-99.
42. Wang L.D., Chen H.G., Guo J.G., Zeng X.J., Hong X.L., Xiong J.J., Wu X.H., Wang X.H., Wang L.Y., Xia G., Hao Y., Chin D.P., Zhou X.N. A strategy to control transmission of Schistosoma japonicum in China. N. Engl. J. Med. 2009, 360:121-128.
43. Williams G.M., Sleigh A.C., Li Y., Feng Z., Davis G.M., Chen H., Ross A.G., Bergquist R., McManus D.P. Mathematical modelling of Schistosomiasis japonica: comparison of control strategies in the People's Republic of China. Acta Trop. 2002, 82:253-262.